The chemist chain begins offering Britain’s inaugural tablet version of Wegovy for weight reduction from today, with thousands having already registered interest.
The retail pharmacy group reported that interest was high even prior to the official rollout, with thousands undergoing consultations to be amongst the initial qualified recipients of the treatment.
This introduction represents a significant broadening of slimming treatment choices in Britain, especially for those uneasy about administering their own injections or who favour a once-daily tablet regimen.
Suitable individuals cleared via the Boots digital health platform may opt for home delivery or in-store collection commencing today.
Pricing commences at £79 for first-time users receiving the minimum 1.5mg strength under a promotional scheme. Established customers will be charged starting at £99.
The tablet incorporates semaglutide, the identical active component found in injectable Wegovy. It operates by replicating the natural GLP-1 hormone to diminish hunger sensations, heighten feelings of satisfaction and delay stomach emptying, enabling reduced food consumption.
Regulatory approval was granted by Britain’s medicines authority the previous month, making this the inaugural GLP-1 tablet sanctioned for weight control in the country.
The chemist chain reported that almost two-thirds of those completing consultations prior to release will be obtaining weight management medication through the retailer for the first time, pending clinical evaluation.
Service users will additionally receive supplementary assistance, comprising internet-based guidance, web-based seminars, a cost-free 10-week lifestyle initiative, monitoring tools for advancement and a 12-month support package following treatment completion.
The oral Wegovy remedy will furthermore become accessible via Boots’ physical store weight management service from 12 July, with assessments currently offered at 62 branches and a further 25 sites planned for addition shortly.
Jamie Kerruish, Chief Healthcare Officer at Boots, stated that the introduction of the new oral Wegovy tablet represents a significant enhancement to their weight management service, forming part of their ongoing commitment to weight control through both in-store assistance, including their newly created specialist weight loss journey support zones, and digital resources accessible through Boots Online Doctor.
The establishment has additionally introduced dedicated weight loss support areas in 70 outlets, stocking health, wellbeing and beauty products intended to assist customers throughout their slimming process.
The medication is accessible for individuals aged 18 and over who fulfil the clinical eligibility requirements. Current recommendations indicate it may be appropriate for those with a BMI of 30 or greater, or 27 or above presenting at least one weight-associated health condition, subsequent to medical evaluation.
Dr Anju Verma, Clinical Lead for Weight Loss at Boots Online Doctor, stated that having an effective oral treatment accessible provides customers and medical professionals with increased options when determining the most suitable treatment strategy.
Weight management is not uniform, and broadening the selection of clinically verified options at varying price levels enables treatment choices to be more precisely matched to an individual’s preferences, way of life and clinical requirements.
It is crucial to bear in mind that weight loss medications do not deliver immediate results. Whether administered as a tablet or injection, optimal results occur when treatment is combined with healthy lifestyle modifications, appropriate clinical assessment, patient education and continuous medical supervision.
Medication can serve as a useful aid, though it proves most effective as a component of a broader, sustained approach to weight management.